Tag Archives: Galena Biopharma

Healthcare Sector Roundup: Hologic (NASDAQ:HOLX), Insulet (NASDAQ:PODD) – HOLX, PODD, JNJ, AVEO, CYTK, GALE

Posted on May 7, 2013 by Thomas Vedder

Investors responded negatively to the healthcare stocks on Monday. Key movement were observed in AVEO Pharmaceuticals, Inc (NASDAQ:AVEO) and Cytokinetics, Inc (NASDAQ:CYTK) on percentage gainers side while Galena Biopharma Inc (NASDAQ:GALE) was prominent stock on percentage gainer side.

Hologic, Inc …

Posted in Healthcare, Latest Headlines | Tagged AVEO, AVEO Pharmaceuticals, CYTK, Cytokinetics, GALE, Galena Biopharma, Hologic, HOLX, Insulet, JNJ, Johnson, NASDAQ:AVEO, NASDAQ:CYTK, NASDAQ:GALE, NASDAQ:HOLX, NASDAQ:PODD, NYSE:JNJ, PODD | Comments Off

Healthcare Stocks News Buzz: Herbalife (NYSE:HLF), Express Scripts (NASDAQ:ESRX) – HLF, ESRX, MRK, DCTH, GALE, THC

Posted on April 30, 2013 by Thomas Vedder

Investors responded positively to the healthcare stocks on Monday. Key movement were monitored in Delcath Systems, Inc (NASDAQ:DCTH) on percentage decliners while Galena Biopharma Inc (NASDAQ:GALE) and Tenet Healthcare Corp (NYSE:THC) were prominent stock on percentage gainers side.

Herbalife Ltd …

Posted in Healthcare, Latest Headlines | Tagged DCTH, Delcath, ESRX, Express Scripts, GALE, Galena Biopharma, Herbalife, HLF, Merck, MRK, NASDAQ:DCTH, NASDAQ:ESRX, NASDAQ:GALE, NYSE:HLF, NYSE:MRK, NYSE:THC, Tenet Healthcare, THC | Comments Off

Morgan Stanley (MS) Shatter Merck (NYSE:MRK) Stock Rating after Quarterly Results – MRK, GALE, TEVA, ANTH, JNJ, HEB, BMY, GSK, NVS

Posted on February 4, 2013 by Geoff Noir

Merck & Co., Inc (NYSE:MRK) stock rationing was lower to market perform by Lee rink Swann while Morgan Stanley shatters their rationing to underweight.

Shares of second biggest drug maker in US plunged on Monday in early trading session as …

Posted in Healthcare, Latest Headlines | Tagged ANTH, Anthera Pharmaceuticals, BMY, Bristol-Myers Squibb, GALE, Galena Biopharma, GlaxoSmithKline, GSK, HEB, Hemispherx BioPharma, JNJ, Johnson & Johnson, Merck, MRK, NASDAQ:ANTH, NASDAQ:GALE, Novartis, NVS, NYSE:BMY, NYSE:GSK, NYSE:JNJ, NYSE:MRK, NYSE:NVS, NYSE:TEVA, NYSEAMEX:HEB, TEVA, Teva Pharmaceutical Industries | Comments Off

Galena Biopharma (NASDAQ:GALE) Stock Down as Unveil Details of Offers of 15.2 Million Units – GALE, ARWR, ISIS, TEVA

Posted on December 19, 2012 by Geoff Noir

Galena Biopharma Inc (NASDAQ:GALE) reported on Tuesday that its sale of 15.2 million units is projected to boost gross proceeds of almost $24.3 million to use for trials of its cancer drug applicants.

Shares of Galena Biopharma plunged 18% to …

Posted in Healthcare, Latest Headlines | Tagged Arrowhead Research, ARWR, GALE, Galena Biopharma, ISIS, NASDAQ:ARWR, NASDAQ:GALE, NASDAQ:ISIS, NYSE:TEVA, TEVA | Comments Off

Aetna (NYSE:AET) Settles Ends Federal Court Lawsuit with $120 Million – AET, CI, UNH, BSX, JNJ, ABT, PFE, AMRN, GALE

Posted on December 10, 2012 by Geoff Noir

On Friday trading session, Aetna (NYSE:AET) declared that it has resolved a class action court case, primarily filed on July 30, 2007, about its practices associated to the payment of accuses for services rendered to Aetna affiliates by health-care suppliers …

Posted in Latest Headlines, Services | Tagged Abbott Laboratories, ABT, AET, Aetna, Amarin, AMRN, Boston Scientific, BSX, CI, Cigna, GALE, Galena Biopharma, JNJ, Johnson, NASDAQ:AMRN, NASDAQ:GALE, NYSE:ABT, NYSE:AET, NYSE:BSX, NYSE:CI, NYSE:JNJ, NYSE:PFE, NYSE:UNH, PFE, Pfizer, UNH, UnitedHealth | Comments Off

Sanofi’s (NYSE:SNY) Genzyme Division Gets Approval for Thyrogen – SNY, MRK, PFE, GALE, ACRX, JNJ, ACHC, SRPT, ABT

Posted on December 7, 2012 by Thomas Vedder

Sanofi’s(NYSE:SNY) Genzyme division has got European Commission authorization of a product label development for the use of Thyrogen, its cure for thyroid cancer.

Thyrogen is used to cure patients with well-distinguished thyroid cancer. The drug is accepted as an adjunctive …

Posted in Healthcare, Latest Headlines | Tagged Abbott Laboratories, ABT, Acadia Healthcare, AcelRx Pharmaceuticals, ACHC, ACRX, GALE, Galena Biopharma, JNJ, Johnson, Merck, MRK, NASDAQ:ACHC, NASDAQ:ACRX, NASDAQ:GALE, NASDAQ:SRPT, NYSE:ABT, NYSE:JNJ, NYSE:MRK, NYSE:PFE, NYSE:SNY, PFE, Pfizer, Sanofi, Sarepta Therapeutics, SNY, SRPT | Comments Off

Stock Market Quotes and Streaming Charts - QuoteDaddy.com Level 2 Stock Quotes from Quote Daddy on Vimeo.

blogs

Lorimer Wilson Analyst

Dian L. Chu "EconMatters"

Paul Ebeling Trading News

Warren Bevan Precious Metals

eStocksDaily.com ("ESD") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities customers should buy or sell for themselves. The employees or affiliates of ESD may hold positions in the stocks or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities. ESD, the authors, the publisher, and all affiliates of ESD assume no responsibility or liability for your trading and investment results. Factual statements on the ESD's website, or in its publications, are made as of the date stated and are subject to change without notice. For ESD full disclaimer and disclosure go to our disclaimer page.It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by ESD are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of ESD's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on ESD's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.